Journal of Contemporary Brachytherapy

Spinal cord-sparing directional palladium-103 brachytherapy for dose escalation to posterior vertebral structures: A cadaveric feasibility study

Tugce Kutuk 1
,
Seth B. Wilson 2
,
Michael Degnan 1
,
Nathan Ritchey 2
,
Jacob Ward 2
,
Mark Damante 3
,
Marshall Harrell 1
,
Alexander Crum 1
,
Raju Raval 1
,
Raj Singh 4
,
Fatemeh Fekrmandi 1
,
Khaled Dibs 1
,
Samantha Morelli 1
,
Daniel Schneider 3
,
Brian Park 3
,
Vikram Chakravarthy 3
,
Joshua Palmer 1

  1. Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA

  2. The Ohio State College of Medicine, Columbus, OH, USA

  3. Department of Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA

  4. Department of Radiation Oncology, Lynn Cancer Institute, Baptist Health South Florida, Boca Raton, FL, USA

J Contemp Brachytherapy 2026

DOI: https://doi.org/10.5114/jcb.2026.165746
Data publikacji online: 2026/11/02
Article file
Spinal cord-sparing.pdf
  1. Costachescu B, Niculescu AG, Iliescu BF et al. Current and emerging approaches for spine tumor treatment. Int J Mol Sci 2022; 23: 15680.
  2. Ratnakumaran R, van As N, Khoo V et al. Patterns of failure after stereotactic body radiotherapy to sacral metastases. Clin Oncol (R Coll Radiol) 2023; 35: 339-346.
  3. Yamada Y, Bilsky MH, Lovelock DM et al. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys 2008; 71: 484-490.
  4. Sahgal A, Atenafu EG, Chao S et al. Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score. J Clin Oncol 2013; 31: 3426-3431.
  5. Mao G, Theodore N. Spinal brachytherapy. Neuro Oncol 2022; 24 (Suppl 6): S62-S68.
  6. Aima M, DeWerd LA, Mitch MG et al. Dosimetric characterization of a new directional low-dose rate brachytherapy source. Med Phys 2018; 10.1002/mp.12994.
  7. Cohen GN, Episcopia K, Lim SB et al. Intraoperative implantation of a mesh of directional palladium sources (CivaSheet): Dosimetry verification, clinical commissioning, dose specification, and preliminary experience. Brachytherapy 2017; 16: 1257-1264.
  8. Taylor RJ, Todor D, Kaplan BJ et al. CivaSheet intraoperative radiation therapy for pancreatic cancer. Brachytherapy 2022; 21: 255-259.
  9. Dault JB, Todor D, Kaplan BJ et al. First report on the feasibility of a permanently implantable uni-directional planar low dose rate brachytherapy sheet for patients with resectable or borderline resectable pancreatic cancer. Brachytherapy 2021; 20: 207-217.
  10. Wu AJ, Youssef I, Cohen GN et al. Prospective evaluation of a novel unidirectional permanent device for intraoperative brachytherapy. Adv Radiat Oncol 2025; 10: 101788.
  11. Okhawere KE, Razdan S, Beksac AT et al. Novel bioabsorbable, low-dose rate brachytherapy device (CivaSheet((R))) with radical prostatectomy and adjuvant external beam radiation for the management of prostate cancer. BJU Int 2025; 135: 782-791.
  12. Nath R, Anderson LL, Luxton G et al. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys 1995; 22: 209-234.
  13. Rivard MJ, Coursey BM, DeWerd LA et al. Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. Med Phys 2004; 31: 633-674.
  14. Bishop AJ, Tao R, Rebueno NC et al. Outcomes for spine stereotactic body radiation therapy and an analysis of predictors of local recurrence. Int J Radiat Oncol Biol Phys 2015; 92: 1016-1026.
  15. Zeng KL, Sahgal A, Husain ZA et al. Local control and patterns of failure for “Radioresistant” spinal metastases following stereotactic body radiotherapy compared to a “Radiosensitive” reference. J Neurooncol 2021; 152: 173-182.
  16. Sahgal A, Chang JH, Ma L et al. Spinal cord dose tolerance to stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2021; 110: 124-136.
  17. Zayed S, Ruschin M, Atenafu EG et al. Prognostic factors for local failure and overall survival in patients with epidural disease at the cauda equina following stereotactic body radiotherapy: a clinical, anatomic and dosimetric analysis. J Neurooncol 2025; 175: 621-631.
  18. Jackson CB, Boe LA, Zhang L et al. Radiation myelitis risk after hypofractionated spine stereotactic body radiation therapy. JAMA Oncol 2025; 11: 128-134.
  19. DeLaney TF, Chen GT, Mauceri TC et al. Intraoperative dural irradiation by customized 192iridium and 90yttrium brachytherapy plaques. Int J Radiat Oncol Biol Phys 2003; 57: 239-245.
  20. Folkert MR, Bilsky MH, Cohen GN et al. Intraoperative 32P high-dose rate brachytherapy of the dura for recurrent primary and metastatic intracranial and spinal tumors. Neurosurgery 2012; 71: 1003-1010; discussion 1010-1011.
  21. Dalle Ore CL, Ames CP, Magill ST et al. Initial experience with intraoperative phosphorous-32 brachytherapy during resection of malignant spinal tumors. World Neurosurg 2018; 115: e785-e793.
  22. Yao L, Cao Q, Wang J et al. CT-guided (125)I seed interstitial brachytherapy as a salvage treatment for recurrent spinal metastases after external beam radiotherapy. Biomed Res Int 2016; 2016: 8265907.
  23. Sharma R, Sagoo NS, Haider AS et al. Iodine-125 radioactive seed brachytherapy as a treatment for spine and bone metastases: A systematic review and meta-analysis. Surg Oncol 2021; 38: 101618.
  24. Li P, Bai Y, Yuan Q et al. Efficacy and safety of CT-guided (125)I seed implantation by coplanar template as a salvage therapy for vertebral metastases after failure of external beam radiation therapy: a retrospective study. Front Oncol 2023; 13: 1084904.
  25. Rogers CL, Theodore N, Dickman CA et al. Surgery and permanent 125I seed paraspinal brachytherapy for malignant tumors with spinal cord compression. Int J Radiat Oncol Biol Phys 2002; 54: 505-513.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Indexed in
pubmed
Integrated with
integrated with publons
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications